Intelligence / Healthtech / New Clinical Trials / Nano-X Imaging
Clinicaltrial registered28 Oct 2026
Nano-X Imaging
28 Oct 2026: Trial registered · Evaluation of the Diagnostic Potential of Nanox.ARC Tomosynthesis System for Different Diseases. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 28 Oct 2026
- Title
- Evaluation of the Diagnostic Potential of Nanox.ARC Tomosynthesis System for Different Diseases
- Conditions
- Fracture, Erosion
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Israel
- Country
- Israel
- Reference
- NCT07900412
- Location
- Israel
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Nano-X Imaging
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Israel
New Clinical Trials
12 NovNovo Nordisk A/Strial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical2 NovNovartis Pharmaceuticalstrial registered · A Study of TRB191 in Patients With Extensive-stage Small Cell Lung CancerClinical30 OctJanssen Research & Development, LLCtrial registered · A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate CancerClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.